Evidence map›Paper›PMID 26573593›Full record

ArticleBMC cancer2015

Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.

Jana Koo, Stephanie Cabarcas-Petroski, John L Petrie, Nicole Diette, Robert J White, Laura Schramm

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Controlling metastatic cancer: the role of phytochemicals in cell signaling.Journal of cancer research and clinical oncology · 2019
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jana KooDepartment of Biological Sciences, St. John's University, Queens, New York, 11439, USA.
Stephanie Cabarcas-PetroskiPennsylvania State University, Beaver Campus, Monaca, PA, 15061, USA.
John L PetrieDepartment of Biology, University of York, Heslington, York, YO10 5DD, UK.
Nicole DietteDepartment of Biological Sciences, St. John's University, Queens, New York, 11439, USA.
Robert J WhiteDepartment of Biology, University of York, Heslington, York, YO10 5DD, UK.
Laura SchrammDepartment of Biological Sciences, St. John's University, Queens, New York, 11439, USA. schramml@stjohns.edu.
St. John's University · USUniversity of York · GBPennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRF2 is a transcription factor required for synthesis of a small group of non-coding RNAs by RNA polymerase III. Overexpression of BRF2 can transform human mammary epithelial cells. In both breast and lung cancers, the BRF2 gene is amplified and overexpressed and may serve as an oncogenic driver. Furthermore, elevated BRF2 can be independently prognostic of unfavorable survival. Dietary soy isoflavones increase metastasis to lungs in a model of breast cancer and a recent study reported significantly increased cell proliferation in breast cancer patients who used soy supplementation. The soy isoflavone daidzein is a major food-derived phytoestrogen that is structurally similar to estrogen. The putative estrogenic effect of soy raises concern that high consumption of soy foods by breast cancer patients may increase tumor growth.

methodsExpression of BRF2 RNA and protein was assayed in ER-positive or -negative human breast cancer cells after exposure to daidzein. We also measured mRNA stability, promoter methylation and response to the demethylating agent 5-azacytidine. In addition, expression was compared between mice fed diets enriched or deprived of isoflavones.

resultsWe demonstrate that the soy isoflavone daidzein specifically stimulates expression of BRF2 in ER-positive breast cancer cells, as well as the related factor BRF1. Induction is accompanied by increased levels of non-coding RNAs that are regulated by BRF2 and BRF1. Daidzein treatment stabilizes BRF2 and BRF1 mRNAs and selectively decreases methylation of the BRF2 promoter. Functional significance of demethylation is supported by induction of BRF2 by the methyltransferase inhibitor 5-azacytidine. None of these effects are observed in an ER-negative breast cancer line, when tested in parallel with ER-positive breast cancer cells. In vivo relevance is suggested by the significantly elevated levels of BRF2 mRNA detected in female mice fed a high-isoflavone commercial diet. In striking contrast, BRF2 and BRF1 mRNA levels are suppressed in matched male mice fed the same isoflavone-enriched diet.

conclusionsThe BRF2 gene that is implicated in cancer can be induced in human breast cancer cells by the isoflavone daidzein, through promoter demethylation and/or mRNA stabilization. Dietary isoflavones may also induce BRF2 in female mice, whereas the converse occurs in males.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorDisease Models, AnimalDNA MethylationFemaleHumansIsoflavonesMaleNeoplasm ProteinsPhytoestrogensPromoter Regions, GeneticProto-Oncogene MasRNA, MessengerRNA, NeoplasmTATA-Binding Protein Associated FactorsBRF1 protein, humanBRF2 protein, humandaidzeinIsoflavonesMAS1 protein, humanNeoplasm ProteinsPhytoestrogensProto-Oncogene MasRNA, MessengerRNA, NeoplasmTATA-Binding Protein Associated FactorsTranscription Factor TFIIIB

Identifiers

PMID26573593
PMCPMC4647806
OpenAlexW2178878860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.